Biopharmaceutical company, Relief Therapeutics Inc (OTCMKTS:RLFTF) on September 9, 2021, announced that APR Applied Pharma Research, the wholly owned subsidiary, has launched affiliates in Germany and Italy, PKU GOLIKE(R) KRUNCH, a convenient chewable tablet for the dietary management of phenylketonuria, a metabolic genetic disorder.
Paolo Galfetti, Chief Executive Officer of APR and President of Relief Europe, said that the firm is addressing a vital need with flexible option for PKU. Galfetti added that the PKU GOLIKE(R) KRUNCH allows patients a tablet that can be a protein substitute. He added that this can ameliorate adherence to therapy and lead to better quality of life.
The company is keen on sales in Germany and Italy , two key markets of the European Union and aims to expand distribution to other markets of Europe. The products of PKU family are meant for special medical purposes.
The PKU GOLIKE(R) family of products are food for special medical purposes. Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, said that the latest launch by APR is a proof of the robustness and flexibility of Physiomimic Technology and is a part of its growing line of products.
Raghuram added that the company is planning on expanding existing commercial infrastructure as well as refine marketing activities for expediting future growth of the product line. The company is also looking at assessing PKU GOLIKE(R) as a prescription products, where majorly in the US have no means to get reimbursed medical foods.
Relief is focused on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale.